Changes in serum levels of liver-related parameters, uric acid, and hemoglobin in patients with type 2 diabetes mellitus under treatment with tofogliflozin-a post-hoc analysis of the UTOPIA study.

The aim of the study was to evaluate the effects of tofogliflozin, a selective sodium-glucose cotransporter 2 inhibitor, on circulating levels of hepatic enzymes, uric acid and hemoglobin levels in patients with type 2 diabetes mellitus (T2DM). We evaluated longitudinal changes in circulating aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (γ-GTP), uric acid, and hemoglobin levels in tofogliflozin (n = 169) and conventional treatment groups (n = 170) using data obtained from the UTOPIA trial, a randomized prospective study conducted to evaluate the efficacy of tofogliflozin in preventing atherosclerosis. Within 104 weeks, tofogliflozin treatment, but not conventional treatment, significantly reduced AST, ALT, and γ-GTP levels. This reduction was significantly greater in the tofogliflozin group than in the conventional group. Stratified analysis showed that, in patients with obesity (defined as body mass index (BMI) ≥ 25.0 kg/m The beneficial effects of tofogliflozin on circulating levels of hepatic enzymes, uric acid, and Hb lasted for 2 years in patients with T2DM. UMIN000017607 (https://www.umin.ac.jp/icdr/index.html). The online version contains supplementary material available at 10.1007/s13340-024-00693-x.

Informations de copyright

© The Japan Diabetes Society 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Déclaration de conflit d'intérêts

Conflict of interestNaoto Katakami received lecture fees from Astellas Pharma Inc., AstraZeneca K.K., Daiichi Sankyo Inc., Eli Lilly Japan K.K., Kowa Company Ltd., Kyowa Hakko Kirin Co. Ltd., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co., Novartis Pharmaceuticals, Novo Nordisk Pharma, Ono Pharmaceutical Co., Taisho Toyama Pharmaceutical Co., Takeda Pharmaceutical Co., Teijin Pharma, Sanofi-Aventis, and Sumitomo Pharma Co. Tomoya Mita has received lecture fees from Kissei Pharmaceutical Co. Ltd., Kowa Pharmaceutical Co., Ono Pharmaceutical Co. Ltd., and Teijin Pharma Company and scholarship donations from MSD K.K., Astellas Pharma Inc., AstraZeneca K.K., Ono Pharmaceutical Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Sanofi-Aventis K.K., Daiichi Sankyo Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Terumo Corporation, Nippon Boehringer Ingelheim Co. Ltd., Novo Nordisk Pharma Ltd., Pfizer Japan Inc., Benefit One Health Care Inc., Mochida Pharmaceutical Co. Ltd., and Nitto Boseki Co. Ltd. as well as funds of endowed chair from MSD K.K. and Takeda Pharmaceutical Company Limited. Yasunori Sato has received lecture fees from Mochida Pharmaceutical Co., Ltd, Eisai Co., Ltd. and Eli Lilly and Company. Hirotaka Watada has received honoraria for lectures from Bayer Pharma Japan, Teijin Pharma Ltd., MSD, Sanofi-Aventis K.K., Novo Nordisk, Nippon Boehringer Ingelheim, Eli Lilly, Sumitomo Pharma, Mitsubishi Tanabe Pharma, Daiichi Sankyo Company, Ltd., Abbott, Kowa Co. Ltd., Taisho Pharmaceutical, Astellas Pharma, Kissei Pharmaceutical Co. Ltd., AstraZeneca K.K., Ono Pharmaceutical Co. Ltd. Sanwa Kagaku, and Takeda Pharmaceuticals and for research activities from Takeda Pharmaceuticals, Nippon Boehringer Ingelheim, Kissei Pharmaceutical, Novo Nordisk, Mitsubishi Tanabe Pharma, Lifescan Japan, Kyowa Kirin, Sumitomo Pharma, Eli Lilly, Teijin Pharma, Taisho Pharmaceutical, Abbott, Ono Pharmaceutical Co. Ltd., Soiken Inc., Sanwa Kagaku, and Kowa. Iichiro Shimomura has received lecture fees from Abbott Japan Co., Ltd., Arkray, Inc., Astellas Pharma Inc., AstraZeneca K.K., Covidien Japan Inc., Daiichi Sankyo Co., Eli Lilly Japan K.K, Johnson & Johnson K.K., MSD K.K., Kowa Company, Ltd., Kyowa Kirin Co. Ltd., Takeda Pharma K.K., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., Nippon Boehringer Ingelheim Co., Novo Nordisk Pharma, Ono Pharmaceutical Co., Sanofi K.K., Sanwa Kagaku Kenkyusho Co., Sumitomo Pharma Co., Taiho Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co. Ltd., Terumo Corporation, and Teijin Pharma; research funds from Cancerscan Inc., Japan Agency for Medical Research and Development (AMED), KOBAYASHI Pharmaceutical Co. Ltd., Kowa Co. Ltd., Kubarahonke Co. Ltd., Rohto Pharmaceutical Co. Ltd., and scholarship donations from Daiichi Sankyo Co., Eli Lilly Japan K.K, Kowa Co. Ltd., Kyowa Kirin Co. Ltd., Mochida Pharmaceutical Co., MSD K.K., Novo Nordisk Pharma, Sanofi K.K., Sumitomo Pharma Co., Takeda Pharma K.K., and Teijin Pharma.